Tag: In the News,Press Releases

BOULDER, Colo.–(BUSINESS WIRE)–Dec. 8, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company’s board of directors. Dr. Kayyem’s diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served…

View as PDF » MEMPHIS, Tenn.–(BUSINESS WIRE)–Dec. 1, 2021– Spesana, the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the…

View as PDF » Data published shows the VeriStrat proteomic test improved overall patient survival by better informing physicians on the selection of immunotherapies to optimally treat NSCLC patients   BOULDER, Colo.–(BUSINESS WIRE)–Nov. 18, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published…

View as PDF » Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing (NGS) test Conference Call and Webcast Today at 9:00 a.m. ET BOULDER, Colo.–(BUSINESS WIRE)–Nov. 15, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its…

View as PDF » BOULDER, Colo.–(BUSINESS WIRE)–Nov. 12, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company will co-present with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), three posters at the 36th Annual Society for Immunotherapy of Cancer (SITC) Nov. 10 –…

View as PDF » BOULDER, Colo.–(BUSINESS WIRE)–Nov. 11, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021. Canaccord Genuity Virtual…

View as PDF » BOULDER, Colo.–(BUSINESS WIRE)–Nov. 1, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15. Biodesix’s management will host a conference call and webcast to…

View as PDF » First data from the ORACLE prospective clinical utility study highlights reduction of invasive procedures on patients with benign nodules BOULDER, Colo.–(BUSINESS WIRE)–Oct. 13, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference. Presentations will include newly…